Bravecto Plus 250 mg / 12.5 mg Spot-on Solution for Medium-sized Cats (>2.8 – 6.25 kg)

País: Reino Unido

Língua: inglês

Origem: VMD (Veterinary Medicines Directorate)

Ingredientes ativos:

Fluralaner, Moxidectin

Disponível em:

MSD Animal Health UK Limited

Código ATC:

QP54AB52

DCI (Denominação Comum Internacional):

Fluralaner, Moxidectin

Forma farmacêutica:

Spot-on solution

Tipo de prescrição:

POM-V - Prescription Only Medicine – Veterinarian

Grupo terapêutico:

Cats

Área terapêutica:

Endectocide

Status de autorização:

Authorized

Data de autorização:

2018-05-08

Características técnicas

Revised: September 2023
AN: 01530/2022
Page 1 of 9
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Bravecto Plus 250 mg / 12.5 mg spot-on solution for medium-sized cats
(>2.8 –
6.25 kg)
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCES:
Each ml of solution contains 280 mg fluralaner and 14 mg moxidectin.
Each pipette delivers:
BRAVECTO PLUS SPOT-ON SOLUTION
PIPETTE CONTENT
(ML)
FLURALANER
(MG)
MOXIDECTIN
(MG)
for medium-sized cats >2.8 – 6.25 kg
0.89
250
12.5
EXCIPIENTS:
Butylhydroxytoluene 1.07 mg/ml
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Spot-on solution.
Clear colourless to yellow solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Cats.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For cats with, or at risk from, mixed parasitic infestations by ticks
or fleas and ear mites,
gastrointestinal nematodes, heartworm or lungworm. The veterinary
medicinal product
is only indicated when use against ticks or fleas and one or more of
the other target
parasites is indicated at the same time.
For the treatment of tick and flea infestations in cats providing
immediate and persistent
flea (_Ctenocephalides felis_) and tick (_Ixodes ricinus) _killing
activity for 12 weeks. Fleas
and ticks must attach to the host and commence feeding in order to be
exposed to the
active substance.
The veterinary medicinal product can be used as part of a treatment
strategy for flea
allergy dermatitis (FAD).
Revised: September 2023
AN: 01530/2022
Page 2 of 9
For the treatment of infestations with ear mites (_Otodectes
cynotis_).
For the treatment of infections with intestinal roundworm (4
th
stage larvae, immature
adults and adults of _Toxocara cati_) and hookworm (4
th
stage larvae, immature adults
and adults of _Ancylostoma tubaeforme_).
When administered repeatedly at a 12-week interval, the veterinary
medicinal product
continuously prevents heartworm disease caused by _Dirofilaria
immitis_ (see details in
section 4.9).
Prevention of aelurostrongylos